TIDMUDG
RNS Number : 1769L
UDG Healthcare Public Limited Co.
17 July 2017
UDG Healthcare announces the acquisition of US-based
healthcare
communications business for up to $35m
17 July 2017: UDG Healthcare plc ("the Group"), a leading
international healthcare services provider, is pleased to announce
the acquisition of Cambridge BioMarketing LLC, a US-based
healthcare communications business, for a total consideration of up
to $35m.
Cambridge BioMarketing is an industry leader in orphan and rare
disease drug launches, a fast-growing area of drug development and
commercialisation. The orphan drug and rare disease market is
forecasted to grow by a CAGR of 11% between 2017 and 2022 to
$209bn, with orphan drugs estimated to account for 21.4% of
prescription sales by 2022(1) . Cambridge BioMarketing also has a
strong creative and digital function in a
market where digital content is becoming increasingly important
for pharmaceutical companies.
The acquisition of Cambridge BioMarketing provides a platform
for growth, specifically in Cambridge, Massachusetts and Oakland,
California, both of which have a strong biotech presence. It
follows the acquisition of Vynamic, a US-based healthcare industry
management consulting firm, announced on 12 July 2017, both of
which are in line with Ashfield's strategy to expand in the US.
Cambridge BioMarketing is being acquired for an initial
consideration of $30 million, with an additional consideration of
up to $5 million payable over the next twelve months, based on the
achievement of agreed financial targets.
Commenting on the announcement, Brendan McAtamney, CEO of UDG
Healthcare plc, said: "The acquisition of Cambridge BioMarketing
provides us with industry-leading expertise in the fast-growing
area of orphan and rare disease drugs and adds further capabilities
in patient-focused communications programmes, an increasing focus
for pharmaceutical companies. The acquisition is in line with our
strategic ambitions to grow our healthcare communications business
in the US and expand the range of services we offer to our global
pharmaceutical customer base."
Cambridge BioMarketing CEO, Maureen Franco said: "We are
thrilled to be joining UDG Healthcare. Being part of the UDG group
provides us with a deeper, complementary suite of services
including healthcare communications, consulting, market access,
clinical services and meeting and events, as well as a global
footprint - allowing us to better serve our clients and providing
increased opportunities for our employees."
Contact:
UDG Healthcare
Alan Ralph Keith Byrne
CFO Head of IR, Strategy & Corporate
Communications
Tel: +353-1-468-9000 Tel: +353-1-468-9000
Powerscourt
Lisa Kavanagh / Jack Hickey
Tel: +44-207-250-1446
Email: udghealthcare@powerscourt-group.com
(1) Source: Evaluate Pharma Orphan Drug Report 2017
Notes to editors
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner
of choice delivering commercial, clinical, communications and
packaging services to the healthcare industry, employing over 8,000
people with operations in 23 countries and delivering services in
over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield,
Sharp and Aquilant.
Ashfield is a global leader in commercialisation services for
the pharmaceutical and healthcare industry, operating across two
broad areas of activity: commercial & clinical services, and
communications services. It focuses on supporting healthcare
professionals and patients at all stages of the product life cycle.
The division provides field and contact centre sales teams,
healthcare communications, patient support, audit, advisory,
medical information and event management services to over 300
healthcare companies.
Sharp is a global leader in contract commercial packaging and
clinical trial packaging services for the pharmaceutical and
biotechnology industries, operating from state of the art
facilities across the US and Europe. Sharp is also a world leader
in 'Track and Trace' serialisation services, which will require all
prescription drugs to have a unique serial code for authentication
and traceability.
Aquilant is a leading provider of outsourced sales, marketing,
distribution and engineering services to the medical and scientific
sectors in the UK, Ireland and the Netherlands.
The company is listed on the London Stock Exchange and is a
constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com
About Cambridge BioMarketing
Founded in 2001, Cambridge BioMarketing is a US based
communications agency specialising in rare orphan diseases with
over 100 employees based across two sites in Cambridge, MA, where
the business is headquartered and in Oakland, CA.
Cambridge BioMarketing's primary service offerings include:
launch readiness support, digital strategy, market analytics,
integrated marketing, patient identification and acquisition,
medical affairs support, line extensions and patient retention and
adherence programmes. Its customers are predominantly
pharmaceutical and biotech companies.
Cambridge is an industry leader in orphan drug launches,
advising pharmaceutical companies on both traditional HCP
(healthcare professional) focused programmes, as well as an
increasing specialism in patient-focused work, an area of growing
focus for pharmaceutical companies.
For more information, please go to: http://cambridgebmg.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQBLGDRUXBBGRS
(END) Dow Jones Newswires
July 17, 2017 02:00 ET (06:00 GMT)
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Apr 2024 to May 2024
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From May 2023 to May 2024